Fig. 1From: Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese childrenEvent-free survival (EFS) for pediatric pro-B ALL according to KMT2A rearrangements and minimal residual disease (MRD). a EFS stratified by KMT2A rearrangements. b EFS stratified by MRD at day 78Back to article page